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Abstract: The objective of this study was to elucidate the effects of hydroxylpropyl-β-
cyclodextrin (HP-β-CD) on the in vitro stability of insulin. It was found that HP-β-CD had 
positive effects on the stability of insulin in acid and base and under high temperature 
conditions. Furthermore, use of HP-β-CD could also increase the stability of disulfide 
bonds which are important to the conformation of insulin. Through 
1H-NMR experiments 
it was found that the protective effect of HP-β-CD was due to complexation with insulin. 
The results suggest that the presence of HP-β-CD could improve the stability of insulin in  
different environments.  
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1. Introduction 
 
Insulin is a hormone produced in the pancreas to decrease the level of sugar in the blood and it was 
the first protein to be sequenced, in 1955, by Frederick Sanger [1,2]. Insulin is the most effective drug 
in diabetes treatment. The insulin molecule consists of 51 amino acid residues and three disulfide 
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bonds. Insulin is made up of two peptide chains, A (with 21 amino acid residues) and B (with 30 
residues), linked by two disulfide bonds connecting cysteine residues A7 and B7 and connecting 
residues A20 and B19. The A chain has an additional internal disulfide bond between residues A6 and 
A11. The stability of disulfide bonds is important to the conformation of insulin. The stability of 
insulin under different conditions has been studied by many researchers. Most studies have dealt with 
the hydrolysis in acid medium into deamidoinsulin products [3]. Decomposition of insulin during 
storage of bovine insulin in the solid state had been studied by Fisher and Porter [4]. Chemical stability 
of insulin was studied by Brange et al. [5]. In a word, the stability of insulin in pharmaceutical 
preparations needs to be improved. 
Cyclodextrins (CDs) are cyclic (α-1, 4)-linked oligosaccharides with 6-, 7- or 8-α-D-glucopyranose, 
units containing a relatively hydrophobic central cavity and a hydrophilic outer surface [6,7]. β-
cyclodextrin (β-CD) consists of seven glucosides. β-CD and its derivatives are widely used as 
solubilizers, stabilizers, absorption promoters, and excipients. 2-Hydroxypropyl-β-cyclodextrin (HP-β-
CD) is a common β-CD derivative with improved water solubility properties [8] and which is also 
more toxicologically benign [9]. It is believed that β-CD can form non-covalent inclusion complexes 
with a wide variety of drugs/proteins. The complexation often alters the physic-chemical and 
biological properties of guest molecules [10]. Hydrophilic β-CD inhibits the adsorption of insulin to 
hydrophobic surfaces and prevents self-aggregating nature of insulin at neutral pH [11,12]. Dotsikas 
and Loukas [13] reported that methyl-β-CD, another β-CD derivative, had a pronounced stabilizing 
effect on insulin decomposition in high temperature. Cyclodextrin (CD) complexation represents a 
unique and effective strategy for improving protein therapy by stabilizing them against aggregation 
[11], thermal denaturation and degradation. In our laboratory it was found that HP-β-CD, casein and 
protamine could offer some positive and useful results, and could protect insulin from degradation 
during transit through the intestinal tract [15]. However, different results were obtained under different 
conditions. Shao et al. [14] reported that hydroxypropyl-β-cyclodextrin did neither increase oral 
bioavailability of insulin, nor it could protect insulin from α-chymotrypsin degradation. Taking this 
information into account, HP-β-CD was chosen to study its effect on insulin under different physical 
and chemical conditions. The investigation was focused on whether acid and base solutions or high 
temperature affected the stability of insulin, and whether HP-β-CD affected it. Moreover, whether HP-
β-CD affected the stability of disulfide bonds or not was investigated. In addition, the complexation of 
insulin with HP-β-CD was characterized in aqueous media by 
1H-NMR chemical shift displacements 
under the addition of HP-β-CD. 
 
2. Results and Discussion 
 
2.1. Effect of HP-β-CD on insulin in acid solution 
 
Most previous studies had dealt with insulin hydrolysis in acid media into deamido products. 
Deamidation takes place at position 21 in the A-chain of insulin (Asn(Asparagine )A21) [3,4]. In an 
acid environment (pH ≤ 2), insulin molecules are in monomer state [16]. This makes them very 
unstable. The amount of insulin in acid solution was determined by HPLC. The results are presented in 
Table 1 and Figure 1. After incubation in pH 1 HCl solution for 16 hours, only 53% of the original Int. J. Mol. Sci. 2009, 10                 
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amount of insulin remained. But about 73% of the insulin remained undegraded when it was treated 
with HP-β-CD. It indicated that HP-β-CD could partially protect insulin from acid degradation. The 
percentage data in Figure 1 (as in the figures that follow) was calculated by comparing the peak areas 
after and before incubation for different time intervals. 
Figure 1. The remaining insulin in acid solution. ▲-▲ indicates the concentration change 
of insulin without HP-β-CD. ■—■ indicates the concentration change of insulin with the 
existence of HP-β-CD. n = 3, mean ± SD. 
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Table 1. Effects of HP-β-CD on 
1H NMR chemical shifts of insulin in 30% CD3COOD. 
No. Side  chain Position  Insulin, chemical shift  With HP-β-CD (Δδ ppm) 
1 
2 
3 
4 
5 
6 
7 
Histidine (B10) 
Histidine (B5) 
Tyrosine (A19) 
Phenylalanine (B1) 
Phenylalanine 
(B24) 
Tyrosine (B26) 
Tyrosine (A14) 
C2 
C2 
C2 and 6 
C2 and 6 
C3 and 5 
C2 and 6 
C3 and 5 
8.3679 
8.2308 
6.9688 
6.8336 
6.7211 
6.6021 
6.4613 
-0.0102 
-0.0135 
-0.0704 
-0.0517 
-0.0016 
-0.0642 
-0.0581 
 
2.2. Effect of HP-β-CD on insulin in base solution 
 
In a basic environment (pH > 9), insulin will disassociate to monomer, and deactivate due to the 
structural change. The concentration of insulin in base solution is determined in the similar way as in 
acid solution.  
As shown in Figure 2, about 51% of the original amount remained after incubation in pH 13 NaOH 
solution for 16 hours. But 82% remained in HP-β-CD/Insulin complex solution. It indicated that HP-β-
CD could also partially protect insulin from degradation in basic solution. What is more, the complex 
between insulin and HP-β-CD was more stable in base solution than in acid solution, which could be 
due to the fact that HP-β-CD was not stable in acid solution. 
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Figure 2. The remaining insulin in base solution. ▲-▲ indicates the concentration change 
of insulin without HP-β-CD. ■—■ indicates the concentration change of insulin with the 
existence of HP-β-CD. n = 3, mean ± SD. 
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2.3. Effect of HP-β-CD on insulin in high temperature 
 
Insulin is unstable in high temperature. Huus et al. [17] reported deamidation of Asn (B3) was 
observed in high temperature environments. The stability of insulin at 55 °C was investigated. The 
results are presented in the Figure 3. As shown in the table and figure, after placement in a 55 °C water 
bath, only 61% insulin remained without HP-β-CD. But 79% insulin remained in HP-β-CD/insulin 
complex solution. Obviously, HP-β-CD helped insulin to resist heat. This result was consistent with 
the report by Dotsikas et al. [13], although they used methyl-β-CD.  
Figure 3. The remaining insulin in a 55 °C water bath. ▲-▲ indicates the concentration 
change of insulin without HP-β-CD. ■—■ indicates the concentration change of insulin 
with the existence of HP-β-CD. N = 3, mean ± SD. 
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2.4. Effect of HP-β-CD on the stability of disulfide bonds 
 
There are three disulfide bonds in insulin molecule, two of which link the two insulin chains. These 
disulfide bonds are critical to the biological activity of insulin, but they are sensitive to both reducing 
and oxidizing reagents. GSH can reduce and lyse the disulfide bond, therefore leading to the 
decomposition of insulin. A buffer containing GSH/GSSG was used in determining the stability of 
disulfide bonds. Different GSH(Glutathione(Reduced))/GSSG(Glutathione (Oxidized)) (mM/mM) Int. J. Mol. Sci. 2009, 10                 
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solutions with GSH/GSSG at 0, 20/1, 40/1 and 60/1 were used to examine the stability of the disulfide 
bond. The degradation products were separated by pH 8.3 PAGE (polyacrylate gel electrophoresis), 
stained with Coomassie Brilliant Blue R-250. The PAGE results are shown in Figures 4A and B. As 
the GSH increased, insulin degradation increased accordingly, but as shown in the graphs, there were 
three degradation product bands when insulin was incubated without HP-β-CD, but only two bands 
when insulin was incubated with HP-β-CD. The main band (insulin) in Figure 4 (B) was much 
brighter, which indicated that more insulin remained. In addition, the HPLC results showed that the 
remaining insulin was more in the solution with HP-β-CD than in the solution without HP-β-CD. This 
indicated that HP-β-CD could increase the stability of disulfide bonds. It would be very interesting to 
know how HP-β-CD increases the stability of disulfide bonds. The mechanism will be the subject of  
further studies in our laboratory. Raman spectroscopy, which is a precise and accurate method for 
studying the character of disulfide bonds could be used. 
 
Figure 4. Effect of HP-β-CD on the stability of disulfide bonds. A and B are the PAGE 
results. The upper graph (A) was insulin without HP-β-CD, the lower graph (B) was 
insulin and HP-β-CD. Lanes 1-4 in (A) and (B) indicated insulin incubated with different 
GSH/GSSG (mM/mM) solutions with 0, 20/1, 40/1, 60/1, GSH/GSSG solution, 
respectively. C is the result of HPLC. ■—■ indicates the remaining insulin with HP-β-CD, 
◆-◆ indicates the remaining insulin without HP-β-CD. 
(A) 
 
(B) 
 
 
(C) 
0
20
40
60
80
100
120
1234
different GSH/GSSG solution
C
i
/
C
(
%
)
 Int. J. Mol. Sci. 2009, 10                 
 
 
2036
2.5. Effects of HP-β-CD on the 
1H-NMR spectrum of insulin 
 
The experiments above indicated that HP-β-CD could partially protect insulin from degradation. In 
an attempt to investigate the interaction of insulin with HP-β-CD, 
1H-NMR spectroscopy in 30% 
CD3COOD was employed (D replaces H of CH3COOH). Figure 5 shows the effects of HP-β-CD on 
the 
1H-NMR spectrum of the aromatic region of insulin. The first two peaks (the 1
st and the 2
nd arrows 
in Figure 5), well separated from the main aromatic region (6.2 – 7.0 ppm) were attributed to the C2 
protons of the B5- and B10-histidines. The inclusion of the aromatic side chains within the cavity of 
HP-β-CD induced chemical shift displacements. The B5 and B10 histidines experienced a significant 
chemical shift, The changes in chemical shifts of A19 (the 3
rd arrow), B1 (the 4
th arrow), B26 (the 6
th 
arrow) and A14 (the 7
th arrow) were among the largest. The B24-phenylalanine (the 5
th arrow) is 
known to be directed towards the hydrophobic interior of the insulin molecule and its ring rotation is 
considerably restricted [18]; no noticeable change in the 
1H-NMR signal of the B24-phenylalanine was 
noted by the addition of HP-β-CD, which may be ascribable to the difficulty of the CDs in gaining 
access to the folded side chain.  
Figure 5. 
1H-NMR spectrum of aromatic region of insulin (4 mM) in the absence of HP-β-
CD (A) and in the presence of HP-β-CD (120 mM) (B) in D2O containing 30% CD3COOD 
at room temperature. 
(A) 
 
(B) 
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Improved insulin stability was observed due to the complexation with HP-β-CD. The 
1H-NMR 
experiment indicated that complexation between HP-β-CD and insulin existed. Furthermore, the 
deamidation sites in insulin molecules might be included into the cone of cyclodextrin molecules, 
which increased the stabilization of the insulin., although there were some difficulties for HP-β-CD in 
approaching the side chain of insulin. Our results are consistent with those of Sajeesh et al. [11] who 
confirmed the formation of HP-β-CD and insulin complexes, using FTIR and fluorescence 
spectroscopic analysis.  
 
3. Experimental Section  
 
3.1. Materials 
 
Insulin was purchased from Wanbang Biopharma Company, Xuzhou (nominal activity of insulin:  
28I U/mg). HP-β-CD (MW: 1,380 Da, molar substitution 0.6) was obtained from Sigma Chemical Co. 
(USA). GSH and GSSG were purchased from Shanghai Biochemistry Pharma Company. Acetonitrile 
was HPLC grade, all other reagents used were of commercially available analytical grade. 
 
3.2. HP-CD/Insulin complex preparation 
 
HP-β-CD/insulin complex was prepared by mixing HP-β-CD and insulin (10:1, w/w), adding a 
small amount of purified water, and stirring for 2 hours at room temperature. The product is dried in a 
vacuum drying oven at room temperature. 
 
3.3. Acid and base incubation 
 
Acid insulin (and HP-β-CD/insulin complex) solution is prepared with 100 mL of 0.1 mol/L HCl 
solution (pH 1) and 10 mg insulin (110 mg HP-β-CD/insulin complex, in which the amount of insulin 
is equivalent to insulin only solution). Base insulin (and insulin complex) solution is prepared with 100 
mL 0.1 mol/L NaOH solution (pH 13) and 10 mg insulin (110 mg HP-β-CD/insulin complex, in which 
the amount of insulin is equivalent to insulin only solution). All solutions were kept in 37 °C water for 
16 hours. Samples were taken from the solutions every four hours and the concentrations  immediately 
determined by HPLC.  
 
3.4. High temperature incubation 
 
Insulin (and HP-β-CD/insulin complex) solution of neutral pH is prepared with 100 mL pH 6.86 
phosphate buffer solutions (PBS). Both solutions were kept in 55 °C water for 16 hours. Samples are 
taken from the solutions every four hours and the concentrations are immediately determined by   
HPLC.  
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3.5. Disulfide bond stability   
 
Insulin was incubated in different GSH/GSSG (mM/mM) solutions at 0 °C for 12 h. The final 
concentration of insulin was 0.2 mmol/L. PAGE was then used to investigate the remaining insulin and 
its degradation products. PAGE was carried out according to Laemmli with minor modifications [19]. 
The running gel, stacking gel and electrode buffer were without sodium dodecyl sulfate (SDS). The 
running gel and stacking gel contained 15% and 4.5% acrylamide, respectively. After electrophoresis, 
the gels were subjected to stain with Coomassie Brilliant Blue R-250. 
 
3.6. High Performance Liquid Chromatography (HPLC) 
 
HPLC was carried out according to Todo et al. [20] with minor modifications. Analyses of 
remaining insulin were carried out by reverse phase HPLC with an isocratic system (Shimadzu Co., 
Kyoto, Japan) using the raw insulin bulk drug as the standard (28.0 U/mg). The HPLC system was 
composed of a pump (LC-10ADvp), diode array detector (SPD-M10Avp), column oven (CTO-
10ASvp), and LC work station (CLASS-LC10). The mobile phase was a 72:28 mixture of 0.2 M 
sodium sulphate buffer (pH 3.0) and acetonitrile at a flow rate of 1.0 mL/min. The column was a 
Shodex Asahipak ODP-506D (4.6 mm × 150 mm, 5 um) (Showa Denko, Ltd., Tokyo) heated at room 
temperature. Ultraviolet absorption was measured at 214 nm. 
 
3.7. Proton-nuclear magnetic resonance (
1H-NMR) spectroscopy 
 
The NMR spectra were measured according to Dotsikas et al. [13] with minor modifications. The  
1H-NMR spectra of insulin (4 mM) in the absence and presence of HP-β-CD (120 mM) were obtained 
at 25 °C with a Bruker Analytik GmbH spectrometer (Avance DRX 400, Houston, USA), operating at 
400.13 MHz, using 30% (v/v) CD3COOD in D2O as solvent. 
1H-NMR chemical shifts were given in 
parts per million (ppm) relative to that of the HOD signal or CD3COOD signal with an accuracy of 
±0.001. The 
1H-NMR signals of aromatic region of insulin were assigned according to the reports of 
Hua and Weiss [20]. 
 
4. Conclusions 
 
There has been a long history of research directed toward the development of novel routes of 
insulin delivery, but development of a proper non-invasive insulin delivery system remains a major 
challenge [22]. The stability of insulin has been extensively studied since insulin had first been used as 
a drug, early in the 1920s [17]. The stability of insulin is critical for its formulation, production and 
storage. Cyclodextrins have been used as stabilizers for many drugs and proteins [7,10,23-25]. 
Previous studies showed that CDs have many positive effects on the stabilization of insulin [13,14,26]. 
This work specifically studied the effect of HP-β-CD on insulin stability when treated with strong acid, 
strong base, and high temperature. Besides, effect of HP-β-CD on the stability of disulfide bonds were 
also been investigated. The results suggested that HP-β-CD could increase the stability of insulin 
under  different conditions. Furthermore, the present study highlighted that HP-β-CD was also useful 
for the stability of the disulfide bonds in insulin. The stability of disulfide bonds is critical to the Int. J. Mol. Sci. 2009, 10                 
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biological activity of insulin. Gould et al. [9] concluded that HP-β-CD was well tolerated in the animal 
species tested (rats, mice and dogs). Taking all this information into account, we conclude that HP-β-
CD could offer positive and useful results in designing insulin preparations. 
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